| Liang, Aibin |
NCT04684147: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 100 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Relapsed or Refractory Acute Lymphoblastic Leukemia | 09/22 | 12/26 | | |
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) |
|
|
| Recruiting | 2 | 80 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed / Refractory Follicular Lymphoma | 12/22 | 12/22 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 12/24 | 09/25 | | |
NCT06182696: OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM |
|
|
| Recruiting | 1/2 | 83 | RoW | OriCAR-017 | OriCell Therapeutics Co., Ltd. | Relapsed and/or Refractory Multiple Myeloma | 11/26 | 08/28 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
| Recruiting | 1/2 | 120 | RoW | Chidamide, HDACi, Fludarabine and cyclophosphamide, FC regimen, Anti-CD19 CAR-T cells, Relma-cel, Axi-cel, Other commercial CAR-T cells, Experimental CAR-T cells | Chinese PLA General Hospital | Non Hodgkin's Lymphoma | 06/24 | 06/25 | | |
NCT05842707: Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1/2 | 48 | RoW | dualCAR-NK19/70 cell, CAR-NK cell | Aibin Liang，MD，Ph.D. | Refractory or Relapsed B-cell Non-Hodgkin Lymphoma | 01/28 | 01/29 | | |
NCT04500431: Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM |
|
|
| Recruiting | 1 | 10 | RoW | Targeting CD269 chimeric antigen receptor engineered T cells, spCART-269 | Shanghai Tongji Hospital, Tongji University School of Medicine | Multiple Myeloma | 07/22 | 12/22 | | |
NCT04317885: A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects |
|
|
| Active, not recruiting | 1 | 25 | RoW | Prizloncabtagene Autoleucel, C-CAR039 | Shanghai Tongji Hospital, Tongji University School of Medicine, Cellular Biomedicine Group Ltd. | Non-Hodgkin's B-cell Lymphoma | 06/23 | 12/23 | | |
NCT06375161: Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients. |
|
|
| Recruiting | 1 | 12 | RoW | anti-CD19-CAR-T cells | Shanghai Tongji Hospital, Tongji University School of Medicine | B Cell Malignancies | 12/25 | 12/39 | | |
NCT06519344: An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients. |
|
|
| Not yet recruiting | 1 | 12 | NA | anti-CD20/CD30-CAR-T Cells | Shanghai Tongji Hospital, Tongji University School of Medicine | B Cell Malignancies | 07/26 | 07/27 | | |
NCT06450067: Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia |
|
|
| Recruiting | N/A | 200 | RoW | | Juventas Cell Therapy Ltd. | B-cell Acute Lymphoblastic Leukemia | 06/26 | 06/29 | | |
NCT05893693: Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia |
|
|
| Recruiting | N/A | 12 | RoW | Biological | Aibin Liang，MD，Ph.D., CARsgen Therapeutics Co., Ltd. | Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse | 01/26 | 01/26 | | |
